PEGINVERA Results

BESREMi was proven to deliver PV control over 7.5 years

The PEGINVERA study was a multicenter, single-arm trial conducted to evaluate the dosing, tolerability, and efficacy of BESREMi in patients with polycythemia vera (PV) (N=51).1

Robust and durable rates of complete hematologic response

Complete hematologic response was observed over 7.5 years in patients treated with BESREMi1

80% (41/51) complete hematologic response rate

Complete hematologic response rate

Defining complete hematologic response

Three blood cells
Hematocrit <45%
A drop
No phlebotomy in
the past 2 months
A group of leukocytes
Leukocyte count
≤10 x 109/L
A group of platelets
Platelet count
≤400 x 109/L

Comprehensive disease control with zero thromboembolic events

Patients treated with BESREMi experienced comprehensive disease control over 7.5 years1

61% (31/51) achieved comprehensive disease control

Achieved comprehensive disease control

Defining comprehensive disease control

Three blood cells
Hematocrit <45%
A drop
No phlebotomy in
the past 2 months
A group of leukocytes
Leukocyte count
≤10 x 109/L
A group of platelets
Platelet count
≤400 x 109/L
A spleen
Normal spleen size*
A blood vessel
Absence of
thromboembolic events
*Longitudinal diameter ≤12 cm for females and ≤13 cm for males, as assessed by ultrasound.

Study Design

Prospective, multicenter, single-arm trial of 7.5 years’ duration

Eligibility/inclusion criteria included a broad range of patients with PV1,2

  1. Newly diagnosed PV with JAK2 positivity
  2. Hydroxyurea (HU) treatment-naïve
  3. High- and low-risk patients
  4. Pretreated with HU/phlebotomy

BESREMi (N=51)

PEGINVERA Stage 11,2

Study Endpoint2

Stage 1: Determination of the maximum tolerated does (MTD)*

PEGINVERA Stage 21,2

Study Endpoint2

Stage 2: Efficacy and safety for comprehensive disease control

Baseline patient characteristics1

Parameter

BESREMi (N=51)

Age (mean), y (range)

56 (35-82)

Sex

Female, % (n)

39% (20)

Male, % (n)

61% (31)

Prior diagnosis of PV,
% (n)

84% (43)

Duration of PV from diagnosis (median)

2.2 years

Previous treatment with HU, % (n)

33% (17)

Newly diagnosed, % (n)

16% (8)

History of major cardiovascular event, % (n)

22% (11)

Hematologic parameters (mean)

Hematocrit, %

45%±4.0%

Leukocytes, 109/L

11.8±5.2

Platelets, 109/L

457±187

Presence of splenomegaly†

Yes, % (n)

31% (16)

*MTD, defined as highest administered dose without dose-limiting toxicities, was determined to be 540 mcg.

†Defined as a longitudinal diameter of >12 cm for women and >13 cm for men.

A graph

Explore additional clinical studies

The LOW-PV study and CONTINUATION-PV study also evaluated the efficacy and safety of BESREMi. Take a closer look at the results on leukocyte and platelet normalization, phlebotomy-free rates, and more.

Review the data in detail
A cross indicating safety

Manageable, long-term safety

BESREMi has a long-term manageable safety profile.1 Adverse events diminished over time after the first 3 months.2

Find out more
Ready to go the distance?
Connect with us

References: 1. BESREMi. Package insert. PharmaEssentia Corporation; 2026. 2. Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762-1769. doi:10.1182/blood-2015-04-637280. 3. Data on file. PharmaEssentia Corporation.

INDICATION

BESREMi is indicated for the treatment of adults with polycythemia vera.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DISORDERS

Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping therapy.

CONTRAINDICATIONS

  • Existence of or history of severe depression, suicidal ideation, or suicide attempt
  • Hypersensitivity to interferons or any inactive ingredients
  • Moderate or severe hepatic impairment
  • History or presence of active serious or untreated autoimmune disease
  • Immunosuppressed transplant recipients

WARNINGS AND PRECAUTIONS

  • Depression and Suicide: Closely monitor patients for any symptoms of psychiatric disorders and, if needed, consider psychiatric consultation and treatment or dosage modifications as listed in the full prescribing information.
  • Endocrine Toxicity: Do not use BESREMi in patients with active serious or untreated endocrine disorders associated with autoimmune disease. Evaluate thyroid function in patients who develop symptoms suggestive of thyroid disease during BESREMi therapy. Discontinue BESREMi in patients who develop endocrine disorders that cannot be adequately managed during treatment with BESREMi.
  • Cardiovascular Toxicity: Patients with a history of cardiovascular disorders should be closely monitored for cardiovascular toxicity during BESREMi therapy. Avoid use of BESREMi in patients with severe or unstable cardiovascular disease or recent stroke or myocardial infarction.
  • Decreased Peripheral Blood Counts: Monitor complete blood counts at baseline, during titration, and every 3-6 months during the maintenance phase.
  • Pancreatitis/Colitis/Pulmonary Toxicity: Interrupt BESREMi treatment in patients with possible pancreatitis, colitis, or pulmonary toxicity and evaluate promptly. Consider discontinuation of BESREMi in patients with confirmed pancreatitis or who show signs or symptoms of serious ulcerative or hemorrhagic colitis, or who develop pulmonary infiltrates or pulmonary function impairment.
  • Ophthalmologic Toxicity: Advise patients to have eye examinations before and during treatment. Discontinue BESREMi in patients who develop new or worsening eye disorders.
  • Hyperlipidemia/Hepatotoxicity/Renal Toxicity: Monitor serum triglycerides, liver enzymes, hepatic function, and serum creatinine at baseline and during therapy. Avoid use of BESREMi in patients with eGFR <30 mL/min. Discontinue BESREMi in patients with persistently marked elevated triglycerides, evidence of hepatic decompensation, or if renal impairment develops during treatment.
  • Dental and Periodontal Toxicity: Patients should have good oral hygiene and regular dental examinations.
  • Dermatologic Toxicity: Consider discontinuation of BESREMi if clinically significant dermatologic toxicity occurs.
  • Driving and Operating Machinery: BESREMi may impact the ability to drive and use machinery. Patients should not drive or use heavy machinery until they know how BESREMi affects their abilities. Patients who experience dizziness, somnolence, or hallucination during BESREMi therapy should avoid driving or using machinery.
  • Embryo-Fetal Toxicity: Based on the mechanism of action, BESREMi can cause fetal harm when administered to a pregnant woman. Obtain a pregnancy test in females of reproductive potential prior to initiating treatment with BESREMi. Advise females of reproductive potential to use an effective method of contraception during treatment with BESREMi and for at least 8 weeks after the final dose. Advise women not to breastfeed during treatment and for 8 weeks after the final dose.

ADVERSE REACTIONS

The most common adverse reactions reported in >40% of patients were influenza-like illness, arthralgia, fatigue, pruritus, nasopharyngitis, and musculoskeletal pain.

DRUG INTERACTIONS

Patients on BESREMi who are receiving concomitant drugs which are CYP450 substrates with a narrow therapeutic index should be monitored to inform the need for dosage modification. Avoid use with myelosuppressive agents, narcotics, hypnotics, or sedatives, and monitor patients receiving the combination for effects of excessive CNS toxicity.
To report SUSPECTED ADVERSE REACTIONS, contact PharmaEssentia at 1-800-999-2449 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information, including Boxed Warning.